<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02485509</url>
  </required_header>
  <id_info>
    <org_study_id>VM-1500-001</org_study_id>
    <nct_id>NCT02485509</nct_id>
  </id_info>
  <brief_title>Study of Safety and Pharmacokinetics in Healthy Volunteers and Safety, Tolerability and Antiviral Activity of VM-1500 in Patients With Human Immunodeficiency Virus-1 Infection</brief_title>
  <official_title>Phase Ib/IIa, Single-Centre, Placebo-Controlled Randomized Study of Safety and Pharmacokinetics in Healthy Volunteers and Safety, Tolerability and Antiviral Activity of VM-1500 in Patients With Human Immunodeficiency Virus-1 Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Viriom</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Viriom</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A combined Phase Ib and IIa randomized, placebo-controlled, double-blind study of VM-1500 in&#xD;
      healthy subjects and in patients with HIV-1 infection that are antiretroviral therapy naïve.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be split into two parts:&#xD;
&#xD;
      Part I: A randomized, placebo-controlled, single dose, double-blind study in healthy&#xD;
      volunteers with 20 mg followed by 40 mg after DSMB approval.&#xD;
&#xD;
      Healthy group: one dose with 1 PK day 12 health volunteers (total): 6 subjects will&#xD;
      randomized (4:2) to VM-1500 20 mg or placebo. After DSMB approval, 6 subjects will be&#xD;
      randomized (4:2) to VM-1500 40 mg or placebo Part II: A randomized, placebo-controlled,&#xD;
      multiple dose, double-blind study for 7 days in patients with HIV infection who are&#xD;
      antiretroviral therapy-naïve. After positive DMSB review the dose will be escalated from 20&#xD;
      mg to 40 mg once daily.&#xD;
&#xD;
      Patient group: 2 PK days (in-house) at day 1 and day 7 16 patients (total): 8 subjects will&#xD;
      be randomized (7:1) to VM-1500 20 mg or placebo once daily for 7 days. After DSMB approval, 8&#xD;
      subjects will be randomized (7:1) to VM-1500 40 mg or placebo once daily for 7 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of VM-1500 in adult healthy subjects and in patients with early-stage chronic HIV-1 infection based on analysis of AEs, laboratory values.</measure>
    <time_frame>about one and half month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK) profile of VM-1500 in healthy subjects (Cmax, AUC, T1/2) and in HIV-1-infected patients.</measure>
    <time_frame>about one and half month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose dependency between VM-1500 plasma levels and corresponding HIV RNA reduction with the administered dosages of VM-1500.</measure>
    <time_frame>about one and half month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virologic activity as measured by plasma HIV RNA following treatment for seven (7) days with VM-1500.</measure>
    <time_frame>about one and half month</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>HIV Infection</condition>
  <arm_group>
    <arm_group_label>20 mg VM-1500/Placebo Healthy group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VM-1500 20 mg or placebo single dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>40 mg VM-1500/Placebo Healthy group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VM-1500 40 mg or placebo single dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>20 mg VM-1500/Placebo Patient group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VM-1500 20 mg or placebo once daily for 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>40 mg VM-1500/Placebo Patient group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VM-1500 40 mg or placebo once daily for 7 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VM-1500/Placebo</intervention_name>
    <description>VM-1500 or Placebo</description>
    <arm_group_label>20 mg VM-1500/Placebo Healthy group</arm_group_label>
    <arm_group_label>20 mg VM-1500/Placebo Patient group</arm_group_label>
    <arm_group_label>40 mg VM-1500/Placebo Healthy group</arm_group_label>
    <arm_group_label>40 mg VM-1500/Placebo Patient group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for Healthy Subjects:&#xD;
&#xD;
          1. Male age between 18-40 years&#xD;
&#xD;
          2. Has been determined healthy by physical examination, assessment of drug abuse, medical&#xD;
             history and vital signs&#xD;
&#xD;
          3. Has normal results for the following screening tests: complete blood count , blood&#xD;
             urea nitrogen, serum creatinine , fasting blood sugar, total bilirubin, aspartate&#xD;
             aminotransferase, alanine aminotransferase, alkaline phosphatase and urinalysis.&#xD;
&#xD;
          4. Negative result for hepatitis B, hepatitis C and HIV antibodies&#xD;
&#xD;
          5. Willing to participate and signed the informed consent form&#xD;
&#xD;
             Inclusion Criteria for Patients:&#xD;
&#xD;
          6. Males or females aged 18 to 65 years&#xD;
&#xD;
          7. HIV-1 infection, as documented by a rapid HIV test or any licensed ELISA test kit and&#xD;
             confirmed by Western blot at any time prior to study entry&#xD;
&#xD;
          8. Antiretroviral therapy naïve.&#xD;
&#xD;
        Exclusion Criteria for Healthy Subjects:&#xD;
&#xD;
          1. Hepatic or kidney disorders or any other disease or disorder which may in the opinion&#xD;
             of the Investigator interfere with the results of the study or threaten the health of&#xD;
             volunteers;&#xD;
&#xD;
          2. Drug intake (including herbal drugs) during the last month;&#xD;
&#xD;
          3. Active alcohol or and/or drug abuse that, in the opinion of the site investigator,&#xD;
             would interfere with adherence to study requirements;&#xD;
&#xD;
          4. Volunteers have taken any investigational drug at least 3 month prior to the start of&#xD;
             the study;&#xD;
&#xD;
          5. Inability to understand the Protocol or follow its instructions;&#xD;
&#xD;
        Exclusion Criteria for Patients:&#xD;
&#xD;
          1. Currently has any active AIDS defining illness&#xD;
&#xD;
          2. Exclusionary resistance mutations defined as evidence of any major NNRTI mutations&#xD;
             according to the current IAS list of HIV-1 Resistance Mutations Associated with Drug&#xD;
             Resistance on any genotype; or evidence of significant NNRTI resistance on any&#xD;
             phenotype performed at any time prior to study entry.&#xD;
&#xD;
          3. Patients who are expected to need systemic antiviral therapy at any time during their&#xD;
             participation in the study.&#xD;
&#xD;
          4. Patients who have received an investigational drug for HIV, HIV vaccine,&#xD;
             immunomodulators, systemic cytotoxic chemotherapy, or other investigational therapy&#xD;
             within 30 days prior to study entry;&#xD;
&#xD;
          5. Acute or chronic viral hepatitis;&#xD;
&#xD;
          6. History or other evidence of renal disease.&#xD;
&#xD;
          7. Abnormal hematological and biochemical parameters within 30 days of Entry (Day 1).&#xD;
&#xD;
          8. Screening ECG QTc value 450 ms.&#xD;
&#xD;
          9. Consumption / administration of concomitant medication.&#xD;
&#xD;
         10. Active alcohol and/or drug abuse that, in the opinion of the site investigator, would&#xD;
             interfere with adherence to study requirements.&#xD;
&#xD;
         11. Positive results on urine screen for drugs of abuse at Screening or Day 1&#xD;
&#xD;
         12. History of immunologically mediated disease.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Faculty of Medicine, Siriraj Hospital</name>
      <address>
        <city>Bangkok</city>
        <state>Wanglang Road</state>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <study_first_submitted>June 18, 2015</study_first_submitted>
  <study_first_submitted_qc>June 25, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 30, 2015</study_first_posted>
  <last_update_submitted>June 25, 2015</last_update_submitted>
  <last_update_submitted_qc>June 25, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

